CNTB (Connect Biopharma Holdings) Construction In Progress : $0.00 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Connect Biopharma Holdings Construction In Progress?

Connect Biopharma Holdings's annual construction in progress declined from Dec. 2021 ($3.70 Mil) to Dec. 2022 ($0.00 Mil) but then stayed the same from Dec. 2022 ($0.00 Mil) to Dec. 2023 ($0.00 Mil).

Connect Biopharma Holdings Construction In Progress Historical Data

The historical data trend for Connect Biopharma Holdings's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Connect Biopharma Holdings Construction In Progress Chart

Connect Biopharma Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

0.29

3.70

Connect Biopharma Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Construction In Progress	Get a 7-Day Free Trial					4.82	-	-	-	-

Connect Biopharma Holdings Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Connect Biopharma Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Connect Biopharma Holdings Ltd (NAS:CNTB) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

12265 El Camino Real, Suite 350, San Diego, CA, USA, 92130

Website

https://www.connectbiopharm.com

Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.